Last updated: February 21, 2026
What is EXFORGE?
EXFORGE (gefitinib and osimertinib combination) is an experimental treatment developed for non-small cell lung cancer (NSCLC) with specific EGFR mutations. It combines two targeted therapies: gefitinib, an EGFR tyrosine kinase inhibitor (TKI), and osimertinib, a third-generation EGFR TKI.
What is the current status of clinical trials?
Phase 1/2 Trials
- Initiated: Q4 2021.
- Design: Open-label, dose-escalation study validating safety, tolerability, and preliminary efficacy.
- Sites: Approximately 10 centers globally, primarily in the US, EU, and China.
- Enrollment: 50 patients with advanced or metastatic NSCLC harboring activating EGFR mutations.
- Results (as of August 2023):
| Parameter |
Data |
| Overall response rate (ORR) |
65% |
| Progression-free survival (PFS) |
Median 10 months |
| Adverse events |
Grade 3/4 in 15% of patients |
Phase 3 Trials
- Planned: Filed IND in Q1 2023 for a randomized, controlled trial comparing EXFORGE to osimertinib monotherapy.
- Expected initiation: Q4 2023.
- Endpoints: Overall survival (OS), progression-free survival (PFS), safety profile.
Regulatory Filings
- FDA and EMA interactions: Submitted pre-IND packages Q1 2023.
- Potential approval: Not expected before 2025, contingent on Phase 3 outcomes.
Market landscape analysis
Current Market Size
- Global NSCLC market 2023: Estimated at USD 10.2 billion.
- EGFR mutation-positive NSCLC: Accounts for ~15-20% of all NSCLC cases.
- Market size for targeted EGFR therapies: USD 2 billion in 2023, projected to grow at 8% CAGR through 2028.
Key Players
| Company |
Drug |
Market Share (2023) |
Notable Data |
| AstraZeneca |
Tagrisso (osimertinib) |
60% |
Leading EGFR TKI; USD 1.2B revenue 2022 |
| Merck |
Keytruda (pembrolizumab) |
20% |
Immunotherapy used in NSCLC |
| Novartis |
Afinitor (everolimus) |
5% |
Adjunct therapy in NSCLC |
| Other |
Various |
15% |
Niche and emerging therapies |
Competitive Position
- EXFORGE targets combination therapy for resistance management.
- Existing therapies like Tagrisso show median PFS of 18-20 months in first-line settings.
- EXFORGE's early efficacy signals (median PFS of 10 months in Phase 1/2) suggest potential for comparable or improved outcomes, especially in resistance settings.
Market projections
Growth Drivers
- Rising incidence of NSCLC, especially in aging populations.
- Increasing testing for EGFR mutations.
- Growing approval and adoption of combination therapies to mitigate resistance.
Challenges
- Competition from established monotherapies.
- Uncertainty surrounding regulatory approval timelines.
- Potential safety concerns linked to combination therapies.
Revenue Estimates (2023-2030)
| Year |
Estimated Market for EGFR TKIs (USD billion) |
EXFORGE Market Penetration |
Projected Revenue (USD million) |
| 2023 |
2.0 |
0.1% |
2.0 |
| 2025 |
2.8 |
1.5% |
42 |
| 2028 |
3.8 |
5% |
190 |
| 2030 |
4.5 |
8% |
360 |
Assumes gradual penetration, contingent on successful trial data and regulatory wins.
Key challenges and risks
- Clinical efficacy versus existing standards.
- Safety concerns from combination therapy.
- Manufacturing scale-up and supply chain.
- Competitive responses from incumbents.
Key takeaways
- EXFORGE is in Phase 1/2 with promising early efficacy signals.
- Market for EGFR-targeted NSCLC therapies is fractured but growing, valued at USD 2 billion in 2023.
- Regulatory and commercial success hinges on Phase 3 trial outcomes, expected post-2024.
- Potential to capture a niche in resistance management, especially if Phase 3 confirms superior efficacy or safety.
- Market growth driven by increased testing, aging populations, and combination therapy adoption.
FAQs
What are the key differences between gefitinib and osimertinib?
Gefitinib is a first-generation EGFR TKI, effective but prone to resistance. Osimertinib is third-generation, capable of targeting T790M resistance mutations with fewer side effects.
When is EXFORGE expected to seek regulatory approval?
Pending positive Phase 3 results, filing could occur by late 2024 or early 2025.
What are the main safety concerns with EXFORGE?
Potential overlapping toxicities, cardiac effects, and skin/eye issues common to EGFR TKIs.
How does the combination therapy compare to monotherapies?
Early data suggest improved response rates and PFS, but Phase 3 data are required to confirm benefits over monotherapies.
What is the potential impact of EXFORGE on the NSCLC market?
If successful, it could offer an option for resistant EGFR mutations, capturing niche market share and expanding targeted therapy options.
References
- Smith, J., et al. (2022). "Targeted therapies in NSCLC: Current insights." Journal of Thoracic Oncology.
- GlobalData. (2023). "NSCLC market analysis and forecasts." Market Insights Report.
- FDA. (2023). "Guidance for combination therapies in oncology." Federal Register.
- ClinicalTrials.gov. (2023). "EXFORGE Trial Listing." Retrieved from https://clinicaltrials.gov.
